Clinical Trial Update: (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis [Phase 2]

View source ↗

Summary

Bezuclastinib is being studied in a Phase 2 trial for advanced systemic mastocytosis and related subtypes; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Systemic Mastocytosis
• Mast Cell Leukemia
• Systemic Mastocytosis
• Systemic Mastocytosis with Associated Hematologic Neoplasm

Drugs mentioned

• Bezuclastinib (bezuclastinib)

Snippet

Sponsor: Cogent Biosciences, Inc. | Conditions: Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN) | Phase 2 | Status: RECRUITING